Exact Sciences – Oncotype MAP™ Pan-Cancer Tissue Test
Dr. Rick Baehner, MD, Chief Medical Officer of Precision Oncology at Exact Sciences discusses the Oncotype MAP™ Pan-Cancer Tissue test for patients with advanced, metastatic, refractory, or recurrent cancer. This rapid genomic tumor profiling test, previously known as PCDx, allows physicians to understand patients’ tumor profiles and effectively recommend targeted therapies or clinical trials based on the biology of their patients’ cancers. He also talks about the broader Oncology Business Unit at Exact Sciences.
Frequently Asked Questions
What is the main topic discussed in this episode of Health Professional Radio?
This episode covers important developments in healthcare, including updates on Cancer. Health Professional Radio brings you expert insights and analysis on the latest medical news affecting healthcare professionals and patients alike.
How can healthcare professionals benefit from this information?
Healthcare professionals can stay informed about the latest developments in Cancer and related fields, enabling them to provide better patient care. Staying current with medical news helps clinicians make evidence-based decisions in their practice.
Where can I find more information about Cancer?
For more detailed information, listen to the full episode on Health Professional Radio and visit hpr.fm for additional resources. You can also subscribe to our podcast for regular updates on healthcare news and expert interviews.
Key Takeaways
- Key Point: Rick Baehner, MD, Chief Medical Officer of Precision Oncology at Exact Sciences discusses the Oncotype MAP™ Pan-Cancer Tissue test for patients with advanced, metastatic, refr…
- Key Point: This rapid genomic tumor profiling test, previously known as PCDx, allows physicians to understand patients’ tumor profiles and effectively recommend targeted therapies or cli…
- Key Point: Rick Baehner, M.D., is the Chief Medical Officer of Precision Oncology at Exact Sciences which is focused on improving the quality of treatment decisions for cancer patients.
- Key Point: He and his colleagues have worked together with leading global oncology clinical research groups to use new molecular diagnostic methods and rigorous clinical studies to develop…
- Key Point: Baehner is also a faculty member at the University of California, San Francisco and has been a leader in breast pathology and cytopathology for more than a decade.
Rick Baehner, M.D., is the Chief Medical Officer of Precision Oncology at Exact Sciences which is focused on improving the quality of treatment decisions for cancer patients. He and his colleagues have worked together with leading global oncology clinical research groups to use new molecular diagnostic methods and rigorous clinical studies to develop and commercialize the Oncotype DX® breast cancer, colon cancer, prostate cancer and liquid biopsy assays.
Dr. Baehner is also a faculty member at the University of California, San Francisco and has been a leader in breast pathology and cytopathology for more than a decade.
Medical Disclaimer
The information provided on this website is for general informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional for medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.



